Tin tức & Cập nhật

Chỉ hiển thị Multimedia
Radiographic progression of interstitial lung disease portends long-term mortality risk

Radiographic progression of interstitial lung disease portends long-term mortality risk

14 Dec 2021

Among patients with systemic sclerosis-interstitial lung disease (SSc-ILD), radiographic progression of ILD over time is predictive of elevated long-term mortality, as shown in a study.

Radiographic progression of interstitial lung disease portends long-term mortality risk

14 Dec 2021
Carbocisteine, gingko leaf extract boost milrinone’s efficacy against COPD complicated by PAH

Carbocisteine, gingko leaf extract boost milrinone’s efficacy against COPD complicated by PAH

09 Dec 2021
AECOPD outcomes unaltered with short-course nonmacrolide therapy

AECOPD outcomes unaltered with short-course nonmacrolide therapy

08 Dec 2021

Short-course nonmacrolide therapy in patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) appears to have no significant effect on outcomes including mortality, progression to ventilation, readmission rate, or prevalence of adverse drug events, a study has shown.

AECOPD outcomes unaltered with short-course nonmacrolide therapy

08 Dec 2021
Child abuse increased during COVID-19 lockdown

Child abuse increased during COVID-19 lockdown

30 Nov 2021 bởiRoshini Claire Anthony

Child abuse rates appear to have increased during the lockdowns imposed to control COVID-19 transmission, according to a study from the US presented at the 2021 American Academy of Pediatrics National Conference & Exhibition (AAP 2021).

Child abuse increased during COVID-19 lockdown

30 Nov 2021
Repurposing a broad-spectrum antiviral drug may help treat asymptomatic, mild COVID-19

Repurposing a broad-spectrum antiviral drug may help treat asymptomatic, mild COVID-19

29 Nov 2021 bởiJairia Dela Cruz

The oral antiviral drug umifenovir, which is used to treat influenza, appears to be beneficial in COVID-19 patients who are asymptomatic or with mild symptoms, with a phase III study showing that the drug is well tolerated and can induce viral clearance within 5 days.

Repurposing a broad-spectrum antiviral drug may help treat asymptomatic, mild COVID-19

29 Nov 2021